SUZHOU, China, and ROCKVILLE, MD, April 24, 2024—Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that results from four clinical studies of the company’s three key drug candidates have been selected for presentations, including an Oral Report, at the 2024 Read More ›

ROCKVILLE, MD, USA, and SUZHOU, China, April 7, 2024—Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, age-related diseases, and chronic hepatitis B (CHB), announced today that it releases the latest results from three preclinical studies of its novel drug candidates olverembatinib, MDM2-p53 inhibitor alrizomadlin (R&D Code: APG-115), FAK/ALK/ROS1 tyrosine Read More ›

Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced its annual results for the full year 2023. During the reporting period, Ascentage Pharma made further strides in revenue generation through its commercialized product, achieved rapid progress with its patient-centric global innovation Read More ›

ROCKVILLE, MD, USA, and SUZHOU, China, March 5, 2024—Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, age-related diseases, and chronic hepatitis B (CHB), announced today that the latest results from three preclinical studies of the company’s novel drug candidates olverembatinib, MDM2-p53 inhibitor alrizomadlin, FAK/ALK/ROS1 tyrosine kinase inhibitor APG-2449, and Read More ›

ROCKVILLE, MD, USA, and SUZHOU, China, February 13, 2024—Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, age-related diseases, and chronic hepatitis B (CHB), announced today that it has received clearance from the US Food and Drug Administration (FDA) to initiate a global registrational Phase III trial of olverembatinib (HQP1351) Read More ›

SUZHOU, China, and ROCKVILLE, MD, January 16, 2024—Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that olverembatinib (R&D Code: HQP1351) has been included in the latest guidelines from the National Comprehensive Cancer Network (NCCN) for the management of  Chronic Myeloid Read More ›

SUZHOU, China, and ROCKVILLE, MD, January 10, 2024—Ascentage Pharma (6855.HK), a commercial stage global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that Dr. Dajun Yang, the company’s Chairman and CEO, gave a speech at the 42nd Annual J.P. Morgan Healthcare Conference. In the presentation, Read More ›

SUZHOU, China, and ROCKVILLE, MD, January 1, 2024—Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it will attend the 42nd J.P. Morgan Healthcare Conference, and Dr. Dajun Yang, its Chairman and CEO, will give a presentation on Ascentage Pharma Read More ›

SUZHOU, China, and ROCKVILLE, MD, December 15, 2023—Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that Prof. Xiaoyuan Gong of the Institute of Hematology and Blood Diseases Hospital, the Chinese Academy of Medical Sciences, has presented the preliminary results from Read More ›

SUZHOU, China, and ROCKVILLE, MD, December 13, 2023—Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it has released updated data from a randomized, controlled, registrational Phase II study of the company’s novel drug candidate, olverembatinib (R&D code: HQP1351), in Read More ›